Exciting Leadership Changes at DBV Technologies
DBV Technologies, a prominent name in biopharmaceutical innovation, has recently made headlines with the appointment of James Briggs as their new Chief Human Resources Officer. This strategic move is aimed at supporting the company's transition from a focused clinical-stage organization to one that is poised for commercial success.
The Role of Chief Human Resources Officer
In his new role, James Briggs will oversee critical initiatives that will guide DBV Technologies in building its infrastructure for commercial operations. With a wealth of experience in human capital management, he is set to play an integral part in the company's growth strategy. Reporting directly to Daniel Tassé, the Chief Executive Officer, James will also be a key member of the Executive Committee.
Gratitude and Vision
Daniel Tassé expressed heartfelt appreciation for James's predecessor, Caroline Daniere, highlighting her remarkable leadership and the positive organizational culture she fostered. He noted, "James brings a unique perspective on talent management, which is crucial as we navigate this pivotal transition." This reflects the company’s commitment to nurturing a robust leadership team.
James Briggs’ Background
Before joining DBV Technologies, James Briggs held a significant position as a Partner at East Bay Human Capital, a specialized consultancy in human resources strategy, organizational design, and change management. He has a proven history of driving organizational success, particularly in his previous role as Chief Executive Officer at MNG Health, where he successfully led a turnaround strategy. His extensive experience also includes leading HR functions at Ciox Health and Ikaria Inc., making him well-equipped for his new position at DBV Technologies.
Looking Ahead
James expressed his enthusiasm about joining DBV Technologies, stating, "This is a pivotal moment for us as we prepare for the transition to commercial success. I am eager to collaborate with this talented leadership team to establish the framework that will further our mission in delivering life-changing treatments to those in need." His vision aligns perfectly with the company's dedication to bringing innovative solutions to the biopharmaceutical landscape.
About DBV Technologies
DBV Technologies is renowned for its commitment to advancing treatment options for food allergies and other unmet medical needs. Their proprietary technology, the VIASKIN® patch, represents a groundbreaking approach in treating food allergies by utilizing epicutaneous immunotherapy (EPIT). This innovative non-invasive treatment seeks to educate the immune system to reduce sensitivity to specific allergens, helping countless individuals, especially children, live healthier lives.
The company's ongoing clinical trials for the VIASKIN Peanut patch demonstrate their dedication to addressing food allergies among toddlers and young children. With headquarters in Châtillon, France, and operations extending to North America, DBV Technologies continues to make significant strides within the healthcare sector.
Investor and Media Contacts
For those interested in learning more about DBV Technologies or seeking investor relations, Katie Matthews is available for inquiries at katie.matthews@dbv-technologies.com. Similarly, media inquiries can be directed to Brett Whelan at brett.whelan@dbv-technologies.com. The company is open for engagement and provides further information on its strategic initiatives and innovations.
Frequently Asked Questions
1. Who is the new Chief Human Resources Officer at DBV Technologies?
James Briggs has been appointed as the new Chief Human Resources Officer at DBV Technologies.
2. What is the mission of DBV Technologies?
DBV Technologies aims to develop innovative treatments for food allergies and other significant medical needs.
3. Where are DBV Technologies' operations located?
The company is headquartered in Châtillon, France, with operations also in Warren, NJ, North America.
4. What is the VIASKIN® patch technology?
VIASKIN® patch technology is an epicutaneous immunotherapy designed to treat food allergies by introducing small doses of allergens through the skin.
5. How can I learn more about DBV Technologies?
You can visit their official website or contact investor relations for detailed inquiries.
